PARPi increases radiotherapy sensitivity of esophageal squamous cell carcinoma by inhibiting XRCC1 expression

• Published in: Fu she yan jiu yu fu she gong yi xue bao Vol. 41; no. 3; p. 030303
• Main Authors: LI Yiping, ZHANG Yufei, SUN Guangzhi, YE Yunyao, SHEN Xiaozhou, HAN Gaohua
• Format: Journal Article
• Language: Chinese
• Published: Science Press 01.06.2023
• Subjects: esophageal squamous cell carcinoma; poly(adp-ribose)polymerase inhibitor; radiotherapy sensitivity; x-ray cross complementing gene-1
• DOI: 10.11889/j.1000-3436.2022-0122
• ISSN: 1000-3436

This study investigated the effect of poly-ADP ribose polymerase inhibitor (PARPi) on X-ray repair cross complementing 1 gene (XRCC1) expression and radiotherapy sensitivity of esophageal squamous cell carcinoma (ESCC). Tissue samples from patients with ESCC treated with irradiation using a linear accelerator were collected to detect the expression of XRCC1 and PARP-1 with immunohistochemical staining, and the effect of their expression on radiotherapy efficacy was evaluated. A linear accelerator was used to irradiate ECA109 cells after treatment with different concentrations of AZD2281 (a PARP inhibitor) to detect the radiotherapy sensitization ratio (SER) of PARPi. An RT-PCR assay was used to assess the relative expression of XRCC1 mRNA in ECA109 cells treated with irradiation and AZD2281 and to explore the effect of PARPi on the transcription of the XRCC1 gene in ECA109 cells after irradiation. Our data indicated that the objective response rate (ORR) of XRCC1-positive patients was lower than that of XRCC1